HMGCLL1是慢性髓性白血病伊马替尼治疗深度分子学反应的预测性生物标志物
该研究在201例慢性髓性白血病(CML)患者中发现HMGCLL1遗传变异与伊马替尼(IM)治疗深度分子学反应(DMR)相关,并在270例验证集中成功重复。功能实验显示小干扰RNA阻断HMGCLL1异构体3可降低BCR-ABL1阳性细胞活力,并伴G0/G1期阻滞。
要点
- HMGCLL1遗传变异可作为CML患者伊马替尼内在敏感性的预测性遗传生物标志物。
- 发现集(n=201)与验证集(n=270)均显示HMGCLL1变异与DMR相关。
- 阻断HMGCLL1异构体3可降低BCR-ABL1阳性细胞活力并诱导G0/G1期阻滞。
核心结论
- HMGCLL1基因多态性是CML患者对伊马替尼治疗内在敏感性的新型遗传生物标志物,可预测DMR。
研究设计与样本
- 研究在发现集201例CML患者中测量HMGCLL1变异与DMR率的关系,并在验证集270例中重复验证。
- 同时通过小干扰RNA阻断HMGCLL1异构体3进行功能研究,并采用RNA测序分析细胞周期。
主要发现
- HMGCLL1遗传变异位于6p12.1,与伊马替尼治疗的内在敏感性相关。
- 小干扰RNA介导阻断HMGCLL1异构体3导致BCR-ABL1阳性细胞活力显著下降,包括K562、CML-T1或BaF3细胞系(伴或不伴ABL1激酶结构域突变如T315I突变)。
- 小鼠CML干细胞和人造血祖细胞活力亦下降。
- RNA测序显示阻断HMGCLL1与G0/G1期阻滞和细胞周期相关。
关键数值与推荐
- 发现集201例CML患者中按HMGCLL1变异测量DMR率,并在验证集270例中成功重复。
- HMGCLL1遗传变异位于6p12.1。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Achieving a deep molecular response (DMR) to tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML) remains challenging and at present, there is no biomarker to predict DMR in this setting. Herein, we report that an HMGCLL1 genetic variant located in 6p12.1 can be used as a predictive genetic biomarker for intrinsic sensitivity to imatinib (IM) therapy. We measured DMR rate according to HMGCLL1 variant in a discovery set of CML patients (n = 201) and successfully replicated it in a validation set (n = 270). We also investigated the functional relevance of HMGCLL1 blockade with respect to response to TKI therapy and showed that small interfering RNA mediated blockade of HMGCLL1 isoform 3 results in significant decrease in viability of BCR-ABL1-positive cells including K562, CML-T1 or BaF3 cell lines with or without ABL1 kinase domain mutations such as T315I mutation. Decreased cell viability was also demonstrated in murine CML stem cells and human hematopoietic progenitor cells. RNA sequencing showed that blockade of HMGCLL1 was associated with G0/G1 arrest and the cell cycle. In summary, the HMGCLL1 gene polymorphism is a novel genetic biomarker for intrinsic sensitivity to IM therapy in CML patients that predicts DMR in this setting.
引用
- Park JH, Woo YM, Youm EM, et al. HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. Leukemia. 2018. PMID: 30555164. doi:10.1038/s41375-018-0321-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。